- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05425719
Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects
A Pivotal, Open Label, Multi-Center, Safety and Pharmacokinetic Study of MB-102 (Relmapirazin) and the Use of the MediBeacon Transdermal GFR Measurement System in Normal and Renal Compromised Subjects for the Evaluation of Kidney Function
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Approximately 50% of participants will have GFR > 70 mL/min/1.73m^2, and approximately 50% of participants will have GFR < 70 mL/min/1.73m^2.
Approximately 50% of participants enrolled in the United States will have a FSS value of I-III, and 50% of participants will be FSS IV-VI. The FSS stratification will not apply to participants enrolled in China because the population demographic is unlikely to support the full FSS spectrum.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Richard B Dorshow, PhD
- Phone Number: 314-735-0967
- Email: rbdorshow@medibeacon.com
Study Locations
-
-
-
Beijing, China, 100034
- Peking University First Hospital
-
Xuzhou, China, 2210029
- Affiliated Hospital of Xuzhou Medical University
-
-
Sichuan
-
Chengdu, Sichuan, China, 610093
- West China Hospital of Sichuan University
-
-
-
-
Florida
-
Edgewater, Florida, United States, 32132
- Velocity Clinical Research
-
-
Illinois
-
Chicago, Illinois, United States, 60643
- Research by Design, LLC
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55114
- Nucleus Network
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27612
- Carolina Phase I Research
-
-
Texas
-
San Antonio, Texas, United States, 78240
- Endeavor Clinical Trials, LLC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Eligible female non-pregnant participants who are either not of child-bearing potential or willing to use adequate contraception during the trial
- Males must be willing to practice abstinence or utilize adequate contraception from dosing day to at least 7 days post-dose
- For women of child-bearing potential, the participant should have a negative serum pregnancy test at screening, and agrees to one of the following acceptable contraceptive methods used consistently and correctly i.e. abstinence, oral contraceptive either combined or progesterone alone; injectable progesterone, implants of levonorgestrel, estrogenic vaginal ring, percutaneous contraceptive patches, IUD device or system or male partner sterilization
- Men will not donate sperm during the study and for 1 month following the last dose of study drug
- Participants who are capable of directly providing informed consent and who can comply with the requirements and restrictions required by the protocol
- Adequate venous access sufficient to allow blood sampling per protocol requirements
Exclusion Criteria:
- Participants positive via PCR testing for COVID-19 (Vaccinated participants without symptoms of COVID-19 are not required to undergo PCR testing but may be tested at the discretion of the study site)
- Recent donation or loss of blood or plasma: 100 mL to 499 mL within 30 days prior to the initial dose of the study medication; or more than 499 mL within 56 days prior to the initial dose of study medication
- Non-steroidal anti-inflammatory (NSAID) use within 3 days of MB-102 dosing
- Participant has participated in a clinical trial and has received an investigational product within the following time ranges: prior to the first dosing day in the current study: either 30 days or 5 half-lives of the investigational product (whichever duration is longer)
- History of skin sensitivity to adhesives (e.g. Band-Aids, surgical tape)
- History of severe allergic hypersensitivity reactions (unacceptable adverse events) or anaphylactoid reaction to any allergen including drugs, MB-102 or other related products (intolerance to a drug is not considered a drug allergy).
- Any characteristics which, in the opinion of the investigator, makes the participant a poor candidate for participation in the clinical trial
- Significant scaring, tattoos or alterations in pigmentation on the sternum or other sensor location testing areas that would alter sensor readings versus other areas of the skin
- Any serious or uncontrolled medical disorder, active infection, physical exam finding, laboratory finding, or psychiatric condition that in the opinion of the investigator would limit the participant's ability to complete study requirements or may put the participant at increased risk or compromise the interpretability of study results.
- Currently receiving dialysis
- Currently anuric
- Positive serum pregnancy test
- Participants with an eGFR > 120 mL/min/1.73m^2
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: eGFR ≥ 70 mL/min/1.73 m^2
Participants with eGFR ≥ 70 mL/min/1.73
m^2 will receive one 130 mg dose of MB-102 and a transdermal sensor placed on their chest.
Blood samples and fluorescent measurements will be collected over 12 hours.
|
18.6 mg/mL in a 7.0 mL volume administered by intravenous injection over 30 - 60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 - 60 seconds
Other Names:
On treatment day, participants will have a transdermal sensor placed on their chest in the area between the shoulders (including the pectoralis and sternum area), and the MediBeacon Transdermal GFR Measurement System will be initiated to collect background fluorescence.
After collection of background fluorescence, participants will then receive a single dose of MB-102.
|
Experimental: eGFR < 70 mL/min/1.73 m^2
Participants with eGFR < 70 mL/min/1.73
m^2 will receive one 130 mg dose of MB-102 and a transdermal sensor placed on their chest.
Blood samples and fluorescent measurements will be collected over 24 hours.
|
18.6 mg/mL in a 7.0 mL volume administered by intravenous injection over 30 - 60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 - 60 seconds
Other Names:
On treatment day, participants will have a transdermal sensor placed on their chest in the area between the shoulders (including the pectoralis and sternum area), and the MediBeacon Transdermal GFR Measurement System will be initiated to collect background fluorescence.
After collection of background fluorescence, participants will then receive a single dose of MB-102.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation of transdermal derived glomerular filtration rate (tGFR) to the plasma-derived indexed glomerular filtration rate (nGFR)
Time Frame: Up to 24 hours
|
Statistical agreement between tGFR and nGFR will be calculated.
|
Up to 24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-emergent adverse events associated with MB-102 administration
Time Frame: Up to 10 days
|
An adverse event is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, temporally associated with the use of a medicinal product, whether or not related to the investigational medical device or drug.
|
Up to 10 days
|
Number of participants with treatment-emergent adverse events associated with the MediBeacon Transdermal GFR Measurement System device
Time Frame: Up to 10 days
|
An adverse event is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, temporally associated with the use of a medicinal product, whether or not related to the investigational medical device or drug.
|
Up to 10 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Richard B Dorshow, PhD, MediBeacon, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MB-100-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Disease
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
-
Centre Hospitalier Saint Joseph Saint Luc de LyonNot yet recruitingKidney Failure, Chronic | Diet Habit | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 3B | Chronic Kidney Disease, Stage 3 (Moderate) | Chronic Kidney Disease Stage 3A (Disorder)France
-
A.C. AbrahamsCompletedEnd Stage Renal Disease | Chronic Kidney Disease | End Stage Kidney Disease | Chronic Kidney FailureNetherlands
-
Far Eastern Memorial HospitalActive, not recruitingMetabolic Syndrome | Chronic Disease | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
Clinical Trials on MB-102
-
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.MediBeaconCompletedKidney Diseases | Kidney Injury | Kidney FailureChina
-
Mustang BioEnrolling by invitationDiffuse Large B Cell Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Hairy Cell Leukemia | Mantle Cell Lymphoma Recurrent | Mantle Cell Lymphoma Refractory | Chronic Lymphocytic Leukemia in Relapse | Small Lymphocytic Lymphoma, Relapsed | Waldenstrom's Macroglobulinemia Recurrent | Follicular B-cell Non-Hodgkin's Lymphoma and other conditionsUnited States
-
MediBeaconRecruitingKidney Diseases | Kidney Injury | Kidney FailureUnited States
-
MediBeaconCompleted
-
MediBeaconNot yet recruitingMacular Degeneration | Diabetic Retinopathy | Retinal Vein Occlusion | RetinopathyUnited States
-
MediBeaconCompletedCrohn DiseaseUnited States
-
University of ThessalyCompletedBody Composition | Physical Fitness | Energy Expenditure | Resting Metabolic RateGreece
-
Ceragem Clinical Inc.Not yet recruitingKyphosis | Cervical Kyphosis | Cervical Lordosis
-
Mustang BioNational Cancer Institute (NCI)RecruitingMantle Cell Lymphoma Recurrent | Mantle Cell Lymphoma Refractory | Small Lymphocytic Lymphoma, Relapsed | Waldenstrom's Macroglobulinemia Recurrent | Follicular B-cell Non-Hodgkin's Lymphoma | B-cell Lymphoma Refractory | Waldenstrom's Macroglobulinemia Refractory | Chronic Lymphoid Leukemia in RelapseUnited States